| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.26 | 8e-06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0007 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0008 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.009 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.01 |